KRAS and non-small cell lung carcinoma: The amalgamation of chemotherapy with immunotherapy has garnered attention for its potential to enhance therapeutic outcomes, possibly via the upregulation of PD-L1 expression engendered by adjuvant chemotherapy.[51] A retrospective study comprising 95 patients with advanced KRAS-mutated NSCLC corroborated this notion.